Compare FLNC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLNC | OLMA |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2021 | 2020 |
| Metric | FLNC | OLMA |
|---|---|---|
| Price | $14.97 | $14.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 9 |
| Target Price | $16.93 | ★ $44.89 |
| AVG Volume (30 Days) | ★ 3.6M | 1.6M |
| Earning Date | 05-06-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.00 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,262,830,000.00 | N/A |
| Revenue This Year | $51.18 | N/A |
| Revenue Next Year | $21.37 | $347.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.46 | $2.86 |
| 52 Week High | $33.51 | $36.26 |
| Indicator | FLNC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 28.57 |
| Support Level | $13.92 | $4.35 |
| Resistance Level | $18.21 | $27.38 |
| Average True Range (ATR) | 0.95 | 1.20 |
| MACD | 0.19 | -0.06 |
| Stochastic Oscillator | 2.43 | 19.24 |
Fluence Energy Inc provides intelligent energy storage and optimization software for renewables and storage. Its energy storage solutions and operational services support a more resilient grid and help unlock the potential of renewable portfolios. The company's offerings include energy storage solutions, recurring operational and maintenance services, and Software-as-a-Service (SaaS) products designed to meet customer business needs, performance requirements, in-house capabilities, and risk profiles. Its service plans offer varying levels of training, maintenance, guarantees, warranties, and support for active system management. The company operates in the Americas, APAC and EMEA, with the majority of revenue coming from the Americas.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.